Young Lab Publications
Young Lab Publications
Selected Publications
Stone S, McPherson JP, Kulkarni RP, Young A (2025). The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors. Nature Reviews Cancer. 2025 Dec 3. Epub ahead of print.
Quandt Z*, Young A*, Barlow GL, Smith JA, Kusmartseva I, Dong S, Shapiro MR, Kang JH, Felton JL, Nguyen VQ, Szot G, Hassoun AA, Perdigoto AL, Herold KC, Nolan G, Bollyky PL, Brusko TM, Nakayama M, Cooper S, Anderson MS (2025). Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. J Immunother Cancer. 13(8):e011818.
Quandt Z, Lucas A, Liang SI, Yang E, Stone S, Fadlullah MZH, Bayless NL, Marr SS, Thompson MA, Padron LJ, Bucktrout S, Butterfield LH, Tan AC, Herold KC, Bluestone JA, Anderson MS, Spencer CN, Young A, Connolly JE (2025). Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. J Immunother Cancer. 13(5):e011545.
Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A*, Daud AI* (2024). Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC Rep. 2(1), 46.
Cina ML, Venegas J, Young A (2023). Stocking the toolbox-Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events. Immunol Rev, 318 (1), 110
Kang JH, Bluestone JA, Young A (2021). Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol, 42(4), 293-311.
Young A, Quandt Z, Bluestone JA (2018). The Balancing Act between Cancer Immunity and Autoimmunity in Response to Cancer Immunol Res, 6(12), 1445-1452.
Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ (2018). A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Res, 78(4), 1003-1016.
Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Cancer Res, 77(17), 4684-4696.
Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH (2014). RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer, 14, 808.